ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
Rhea-AI Summary
ClearPoint Neuro (NASDAQ: CLPT) will release its fourth quarter and full year 2025 financial results on March 17, 2026 after market close. A live broadcast and teleconference for investors and analysts is scheduled for 4:30 p.m. ET / 1:30 p.m. PT.
A replay will be available through April 16, 2026, and an online archive will be posted on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – CLPT
In the Mar 6 session, CLPT gained 8.11%, reflecting a notable positive market reaction. Argus tracked a peak move of +38.1% during that session. Our momentum scanner triggered 58 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Regulatory certification | Positive | +10.3% | EU MDR certification for Navigation Software 3.0.2 enabling broader EU access. |
| Jan 12 | Prelim revenue update | Positive | +4.9% | Preliminary Q4 and 2025 revenue with 20% growth and 2026 guidance. |
| Nov 20 | Acquisition close | Positive | +2.3% | Completion of IRRAS acquisition adding IRRAflow and >50 customers. |
| Nov 06 | Quarterly earnings | Positive | -13.3% | Q3 2025 results with revenue growth and high gross margin plus CAL launch. |
| Nov 06 | Acquisition agreement | Positive | -13.3% | Agreement to acquire IRRAS with expected 2026 combined revenue outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product, acquisition, and revenue updates often saw positive reactions, but the last earnings-related and acquisition-agreement headlines coincided with notable share price declines.
Over the last several months, CLPT has reported multiple growth and expansion milestones. On Nov 6, 2025, Q3 2025 results showed revenue of $8.9M and 63% gross margin but the stock fell 13.27%. The IRRAS acquisition agreement and subsequent completion in Nov 2025 added neurocritical care scale. Preliminary 2025 revenue and 2026 guidance on Jan 12, 2026 and EU MDR certification on Jan 22, 2026 were followed by positive price moves. Today’s earnings-date announcement fits into this ongoing cadence of financial and operational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 fourth quarter and full year on Tuesday, March 17th, after the market close.
Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 fourth quarter and full year results on Tuesday, March 17th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until April 16th, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, timelines for regulatory approval and commercialization of its biotech partners' gene and cell therapies, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's ability to market, commercialize and achieve broader market acceptance for the products and services offered by the Company; the regulatory requirements for approval and pace of market adoption of the gene and cell therapies under development by the Company's biotech partners; the Company's biotech partner's continued use of the Company's products and services in their delivery of gene and cell therapies; the Company's ability to maintain its current relationships with its biotech partners or enter into relationships with new partners; the Company's ability to continue to build and maintain the infrastructure and personnel needed to allow for widespread adoption of intracranial administration of gene and cell therapies; the future market for the Company's preclinical services; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company's failure to integrate IRRAS into its business in accordance with expectations; and deviations from the expected market potential of the IRRAS products. For a detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire